SG11201907356SA - Piperidine-substituted mnk inhibitors and methods related thereto - Google Patents
Piperidine-substituted mnk inhibitors and methods related theretoInfo
- Publication number
- SG11201907356SA SG11201907356SA SG11201907356SA SG11201907356SA SG11201907356SA SG 11201907356S A SG11201907356S A SG 11201907356SA SG 11201907356S A SG11201907356S A SG 11201907356SA SG 11201907356S A SG11201907356S A SG 11201907356SA SG 11201907356S A SG11201907356S A SG 11201907356SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- formula
- compounds
- pct
- mnk
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- NZSLSTXKPQAVHL-UHFFFAOYSA-N 2-$l^{1}-oxidanylisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N([O])C(=O)C2=C1 NZSLSTXKPQAVHL-UHFFFAOYSA-N 0.000 abstract 1
- 235000001018 Hibiscus sabdariffa Nutrition 0.000 abstract 1
- 240000004153 Hibiscus sabdariffa Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
NN NH H N N 00 CZ (R3)„ (I), C (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 23 August 2018 (23.08.2018) WIPO I PCT ill~~~~~~~~ 011101VIIIVIIIVIII olo HE HE mum° oimIE (10) International Publication Number WO 2018/152117 Al (51) International Patent Classification: A61K 31/445 (2006.01) C07D 247/02 A61K 31/4523 (2006.01) C07D 471/04 A61K 31/506 (2006.01) C07D 471/10 (2006.01) (2006.01) (2006.01) (21) International Application Number: PCT/US2018/018022 (22) International Filing Date: 13 February 2018 (13.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/458,671 14 February 2017 (14.02.2017) US (71) Applicant: EFFECTOR THERAPEUTICS, INC. [US/US]; 11180 Roselle Street, San Diego, CA 92121 (US). (72) Inventors: ERNST, Justin, T.; 4288 Kerwood Court, San Diego, CA 92130 (US). SPRENGELER, Paul, A.; 8706 Gracilior Court, Escondido, CA 92026 (US). REICH, Siegfried, H; 5940 La Jolla Mesa Drive, La Jolla, CA 92037 (US). SPERRY, Samuel; 1247 Saxony Road, Encinitas, CA 92024 (US). (74) Agent: PINO, Mark, J.; Mintz Levin Cohn Ferris Glovsky and Popeo, PC, 701 Pennsylvania Avenue, NW, Suite 900, Washington, DC 20004 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: PIPERIDINE-SUBSTITUTED MNK INHIBITORS AND METHODS RELATED THERETO (57) : The present invention relates to compounds according to Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof where- in X 1 , X 2 , R 1 , R 2 ' R 3 and n are as defined herein. Also described are pharmaceu- tically acceptable compositions of Formula (I) compounds as well as methods for utilizing the compounds of Formula (I) and the pharmaceutically acceptable com- positions of Formula (I) compounds as inhibitors of Mnk as well as therapeutics for the treatment of diseases such as cancer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762458671P | 2017-02-14 | 2017-02-14 | |
| PCT/US2018/018022 WO2018152117A1 (en) | 2017-02-14 | 2018-02-13 | Piperidine-substituted mnk inhibitors and methods related thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201907356SA true SG11201907356SA (en) | 2019-09-27 |
Family
ID=63106539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201907356SA SG11201907356SA (en) | 2017-02-14 | 2018-02-13 | Piperidine-substituted mnk inhibitors and methods related thereto |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20180228803A1 (en) |
| EP (1) | EP3582776B1 (en) |
| JP (2) | JP2020507588A (en) |
| KR (1) | KR20190117013A (en) |
| CN (1) | CN110719781A (en) |
| AU (2) | AU2018220840A1 (en) |
| BR (1) | BR112019016707A2 (en) |
| CA (1) | CA3053493A1 (en) |
| CL (1) | CL2019002297A1 (en) |
| CO (1) | CO2019009423A2 (en) |
| DK (1) | DK3582776T3 (en) |
| EA (1) | EA201991894A1 (en) |
| ES (1) | ES2969988T3 (en) |
| FI (1) | FI3582776T3 (en) |
| IL (1) | IL268619B (en) |
| MX (1) | MX2019009653A (en) |
| PE (1) | PE20191349A1 (en) |
| PH (1) | PH12019550140A1 (en) |
| SG (1) | SG11201907356SA (en) |
| TW (1) | TWI762579B (en) |
| WO (1) | WO2018152117A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3053493A1 (en) | 2017-02-14 | 2018-08-23 | Effector Therapeutics, Inc. | Piperidine-substituted mnk inhibitors and methods related thereto |
| MX2021004763A (en) | 2018-10-24 | 2021-06-08 | Effector Therapeutics Inc | Crystalline forms of mnk inhibitors. |
| CN111484494B (en) * | 2019-01-29 | 2022-09-13 | 诺沃斯达药业(上海)有限公司 | Polycyclic compounds that inhibit MNK1 and MNK2 |
| BR112022009563A2 (en) | 2019-11-18 | 2022-08-02 | Jumbo Drug Bank Co Ltd | PYROLOTRIAZINE COMPOUNDS ACTING AS A MNK INHIBITOR |
| EP4200296A1 (en) * | 2020-08-20 | 2023-06-28 | Hepagene Therapeutics (HK) Limited | Mnk inhibitors |
| BR112023023189A2 (en) | 2021-05-08 | 2024-01-30 | Jumbo Drug Bank Co Ltd | COMPOUND, CRYSTALLINE FORMS A AND B OF A COMPOUND, METHOD OF PREPARATION FOR CRYSTALLINE FORM A OF A COMPOUND, AND, USE OF THE COMPOUND, CRYSTALLINE FORMS A AND B AND CRYSTALLINE FORMS PREPARED BY THE METHOD |
| CN114736205B (en) * | 2022-03-31 | 2023-03-03 | 武汉九州钰民医药科技有限公司 | Preparation method of compound Tomivosertib |
| CN114853756B (en) * | 2022-03-31 | 2023-03-28 | 武汉九州钰民医药科技有限公司 | Preparation process of compound Tomivosertib |
| WO2024017229A1 (en) * | 2022-07-19 | 2024-01-25 | 成都嘉葆药银医药科技有限公司 | Use of pyrrolotriazine compound in preparation of anti-tumor drug |
| CN116425750A (en) * | 2023-02-10 | 2023-07-14 | 诺沃斯达药业(上海)有限公司 | Salt and crystal of MNK inhibitor compound and preparation method thereof |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5491144A (en) | 1991-05-30 | 1996-02-13 | Ciba-Geigy Corporation | Substituted diaminophthalimides and analogues |
| WO2002098428A1 (en) | 2001-06-05 | 2002-12-12 | Lilly Icos Llc | Tetracyclic compounds as pde5-inhibitors |
| ES2359233T3 (en) | 2001-10-29 | 2011-05-19 | Boehringer Ingelheim International Gmbh | HOMOLOGICAL PROTEINS OF THE MNK KINASE INVOLVED IN THE REGULATION OF ENERGY HOMEOSTASIS AND ORGANULAR METABOLISM. |
| US20050012622A1 (en) | 2003-05-19 | 2005-01-20 | Sutton William R. | Monitoring and control of sleep cycles |
| TWI301760B (en) | 2004-02-27 | 2008-10-11 | Merz Pharma Gmbh & Co Kgaa | Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors |
| US7488745B2 (en) | 2004-07-16 | 2009-02-10 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
| TW200613272A (en) | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
| WO2006135783A2 (en) | 2005-06-10 | 2006-12-21 | Wisconsin Alumni Research Foundation | Compositions and methods for modulating angiogenesis |
| WO2007021309A1 (en) | 2005-08-12 | 2007-02-22 | Astrazeneca Ab | Substituted isoindolones and their use as metabotropic glutamate receptor potentiators |
| ES2340093T3 (en) | 2006-06-22 | 2010-05-28 | Biovitrum Ab (Publ) | PIRAZINE AND PIRIDINE DERIVATIVES AS INHIBITORS OF CINASA MNK. |
| EP1889847A1 (en) | 2006-07-10 | 2008-02-20 | DeveloGen Aktiengesellschaft | Pyrrolopyrimidines for pharmaceutical compositions |
| EP2727909A1 (en) | 2007-03-16 | 2014-05-07 | The Scripps Research Institute | Inhibitors of focal adhesion kinase |
| GB0706072D0 (en) | 2007-03-28 | 2007-05-09 | Sterix Ltd | Compound |
| JP2011504474A (en) | 2007-11-22 | 2011-02-10 | ベーリンガー インゲルハイム インテルナツィオナール ゲゼルシャフト ミット ベシュレンクテル ハフツング | Use of Mnk inhibitors to treat Alzheimer's disease |
| JP2009173629A (en) | 2007-12-21 | 2009-08-06 | Banyu Pharmaceut Co Ltd | New spiroindane derivative having rsk1 inhibition |
| WO2009112445A1 (en) | 2008-03-10 | 2009-09-17 | Novartis Ag | Method of increasing cellular phosphatidyl choline by dgat1 inhibition |
| US8486953B2 (en) * | 2008-08-26 | 2013-07-16 | Boehringer Ingelheim International Gmbh | Thienopyrimidines for pharmaceutical compositions |
| EP2355819A2 (en) | 2008-11-12 | 2011-08-17 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Treating cancer by modulating a mnk |
| TWI468402B (en) | 2009-07-31 | 2015-01-11 | 必治妥美雅史谷比公司 | Compounds for the reduction of β-amyloid production |
| US8637525B2 (en) | 2009-07-31 | 2014-01-28 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
| EP2462123B1 (en) | 2009-08-04 | 2013-10-02 | Merck Sharp & Dohme Corp. | 4,5,6-trisubstituted pyrimidine derivatives as factor ixa inhibitors |
| US8604217B2 (en) | 2009-11-12 | 2013-12-10 | Selvita S.A. | Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent |
| WO2011106168A1 (en) | 2010-02-24 | 2011-09-01 | Dcam Pharma Inc | Purine compounds for treating autoimmune and demyelinating diseases |
| SG189038A1 (en) | 2010-10-01 | 2013-05-31 | Bayer Ip Gmbh | Substituted n-(2-arylamino)aryl sulfonamide-containing combinations |
| CA2818853A1 (en) | 2010-11-30 | 2012-06-07 | Gilead Pharmasset Llc | 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus |
| US9938269B2 (en) | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| US9447087B2 (en) | 2011-09-23 | 2016-09-20 | University Of Utah Research Foundation | Galactokinase inhibitors for the treatment and prevention of associated diseases and disorders |
| WO2013100632A1 (en) | 2011-12-30 | 2013-07-04 | Hanmi Pharm Co., Ltd. | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES |
| CA2868966C (en) | 2012-03-29 | 2021-01-26 | Francis Xavier Tavares | Lactam kinase inhibitors |
| US10280168B2 (en) | 2012-03-30 | 2019-05-07 | Agency For Science, Technology And Research | Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof |
| GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
| WO2013151975A1 (en) | 2012-04-02 | 2013-10-10 | Northeastern University | Compositions and methods for the inhibition of methyltransferases |
| JP2015518842A (en) | 2012-05-21 | 2015-07-06 | バイエル ファーマ アクチエンゲゼルシャフト | Substituted pyrrolopyrimidine |
| TW201412740A (en) | 2012-09-20 | 2014-04-01 | Bayer Pharma AG | Substituted pyrrolopyrimidinylamino-benzothiazolones |
| WO2014072244A1 (en) | 2012-11-09 | 2014-05-15 | Boehringer Ingelheim International Gmbh | Sulfoximine substituted quinazolines for pharmaceutical compositions |
| GB2508652A (en) | 2012-12-07 | 2014-06-11 | Agency Science Tech & Res | Heterocyclic piperazine derivatives |
| US9211300B2 (en) | 2012-12-19 | 2015-12-15 | Idenix Pharmaceuticals Llc | 4′-fluoro nucleosides for the treatment of HCV |
| CA2901527A1 (en) | 2013-02-20 | 2014-08-28 | Bayer Pharma Aktiengesellschaft | Substituted-imidazo[1,2-b]pyridazines as mknk1 inhibitors |
| TW201605867A (en) | 2013-11-20 | 2016-02-16 | 拜耳製藥公司 | Thienopyrimidines |
| TWI713455B (en) | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | Mnk inhibitors and methods related thereto |
| TN2017000258A1 (en) | 2014-12-19 | 2018-10-19 | Bayer Pharma AG | Pyrazolopyridinamines as mknk1 and mknk2 inhibitors |
| WO2016172010A1 (en) * | 2015-04-20 | 2016-10-27 | Effector Therapeutics, Inc. | Inhibitors of immune checkpoint modulators for use in treating cancer and infections |
| CN108602814A (en) | 2015-10-29 | 2018-09-28 | 效应治疗股份有限公司 | Inhibit pyrrolo--, pyrazolo-, imidazo-pyrimidine and the pyridine compounds of MNK1 and MNK2 |
| JP6892444B2 (en) | 2015-10-29 | 2021-06-23 | イーフェクター セラピューティクス， インコーポレイテッド | Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of MNK1 and MNK2 |
| WO2017087808A1 (en) | 2015-11-20 | 2017-05-26 | Effector Therapeutics, Inc. | Heterocyclic compounds that inhibit the kinase activity of mnk useful for treating various cancers |
| GB201520500D0 (en) | 2015-11-20 | 2016-01-06 | Medical Res Council Technology | Compounds |
| GB201520499D0 (en) | 2015-11-20 | 2016-01-06 | Medical Res Council Technology | Compounds |
| WO2017117052A1 (en) | 2015-12-31 | 2017-07-06 | Effector Therapeutics, Inc. | Mnk biomarkers and uses thereof |
| TWI808067B (en) * | 2016-12-19 | 2023-07-11 | 美商雅酶股份有限公司 | Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof |
| CA3053493A1 (en) | 2017-02-14 | 2018-08-23 | Effector Therapeutics, Inc. | Piperidine-substituted mnk inhibitors and methods related thereto |
| CA3064000A1 (en) | 2017-05-24 | 2018-11-29 | Effector Therapeutics, Inc. | Methods and compositions for cellular immunotherapy |
| MX2020004756A (en) | 2017-11-16 | 2020-08-20 | Novartis Ag | Combination therapies. |
| US20200297696A1 (en) | 2017-11-21 | 2020-09-24 | Saint Louis University | P38 inhibitors for the treatment of fshd |
| MX2021004763A (en) | 2018-10-24 | 2021-06-08 | Effector Therapeutics Inc | Crystalline forms of mnk inhibitors. |
-
2018
- 2018-02-13 CA CA3053493A patent/CA3053493A1/en active Pending
- 2018-02-13 BR BR112019016707A patent/BR112019016707A2/en unknown
- 2018-02-13 TW TW107105327A patent/TWI762579B/en active
- 2018-02-13 FI FIEP18754330.1T patent/FI3582776T3/en active
- 2018-02-13 US US15/895,523 patent/US20180228803A1/en not_active Abandoned
- 2018-02-13 KR KR1020197026790A patent/KR20190117013A/en not_active Application Discontinuation
- 2018-02-13 ES ES18754330T patent/ES2969988T3/en active Active
- 2018-02-13 PE PE2019001676A patent/PE20191349A1/en unknown
- 2018-02-13 EA EA201991894A patent/EA201991894A1/en unknown
- 2018-02-13 AU AU2018220840A patent/AU2018220840A1/en not_active Abandoned
- 2018-02-13 SG SG11201907356SA patent/SG11201907356SA/en unknown
- 2018-02-13 EP EP18754330.1A patent/EP3582776B1/en active Active
- 2018-02-13 DK DK18754330.1T patent/DK3582776T3/en active
- 2018-02-13 JP JP2019543809A patent/JP2020507588A/en active Pending
- 2018-02-13 MX MX2019009653A patent/MX2019009653A/en unknown
- 2018-02-13 WO PCT/US2018/018022 patent/WO2018152117A1/en active Application Filing
- 2018-02-13 CN CN201880011685.6A patent/CN110719781A/en active Pending
- 2018-12-27 US US16/233,507 patent/US11083727B2/en active Active
-
2019
- 2019-08-09 PH PH12019550140A patent/PH12019550140A1/en unknown
- 2019-08-11 IL IL268619A patent/IL268619B/en unknown
- 2019-08-13 CL CL2019002297A patent/CL2019002297A1/en unknown
- 2019-08-29 CO CONC2019/0009423A patent/CO2019009423A2/en unknown
-
2021
- 2021-08-06 US US17/396,187 patent/US11878015B2/en active Active
-
2022
- 2022-04-29 AU AU2022202864A patent/AU2022202864B2/en active Active
- 2022-09-29 JP JP2022156442A patent/JP2022185050A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220096472A1 (en) | 2022-03-31 |
| US11878015B2 (en) | 2024-01-23 |
| PE20191349A1 (en) | 2019-09-30 |
| US11083727B2 (en) | 2021-08-10 |
| ES2969988T3 (en) | 2024-05-23 |
| TWI762579B (en) | 2022-05-01 |
| CO2019009423A2 (en) | 2019-09-09 |
| KR20190117013A (en) | 2019-10-15 |
| TW201835076A (en) | 2018-10-01 |
| JP2022185050A (en) | 2022-12-13 |
| PH12019550140A1 (en) | 2020-06-01 |
| CL2019002297A1 (en) | 2019-11-08 |
| BR112019016707A2 (en) | 2020-04-07 |
| CA3053493A1 (en) | 2018-08-23 |
| AU2022202864B2 (en) | 2024-06-06 |
| US20190275039A1 (en) | 2019-09-12 |
| IL268619A (en) | 2019-10-31 |
| MX2019009653A (en) | 2019-12-19 |
| AU2018220840A1 (en) | 2019-09-19 |
| AU2022202864A1 (en) | 2022-05-19 |
| CN110719781A (en) | 2020-01-21 |
| EP3582776A4 (en) | 2020-09-02 |
| EP3582776B1 (en) | 2023-11-08 |
| WO2018152117A1 (en) | 2018-08-23 |
| EA201991894A1 (en) | 2020-02-05 |
| EP3582776A1 (en) | 2019-12-25 |
| FI3582776T3 (en) | 2024-01-03 |
| US20180228803A1 (en) | 2018-08-16 |
| JP2020507588A (en) | 2020-03-12 |
| DK3582776T3 (en) | 2024-01-08 |
| IL268619B (en) | 2022-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201804132UA (en) | Eif4-a-inhibiting compounds and methods related thereto | |
| SG11201900135YA (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
| SG11201807301SA (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201809714TA (en) | Piperidines as menin inhibitors | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201908604YA (en) | Fused imidazo-piperidine jak inhibitor compound | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201908598PA (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201805940QA (en) | Benzopyrazole compounds and analogues thereof | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201811442UA (en) | Formulation of a peptide vaccine | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201900405XA (en) | Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia | |
| SG11201408617PA (en) | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201909376TA (en) | Crystalline forms of a jak inhibitor compound | |
| SG11201901251SA (en) | Aminopyrimidines as alk inhibitors |